Phase II study of Lurbinectedin and Irinotecan in young adults and adults with advanced desmoplastic small round cell tumour (DSRCT).
Contact Information for Access
Status
IN ATTIVAZIONE
Objective of the study
Assess the percentage of objective responses (Overall Response Rate—ORR) as defined by the RECIST version 1.1 criteria.
DSRCT
Sponsor: Italian Sarcoma Group
Medication
Lurbinectidine, Irinotecan.
Who is eligible to participate in the study?
Patients aged ≥15 years with a diagnosis of advanced DSRCT, centrally confirmed histologically and molecularly (presence of the EWSR1-WT1 translocation), with relapsed/progressive disease following treatment with at least one prior anthracycline-based chemotherapy regimen (considering chemotherapy administered for the primary tumor) and no more than 3 prior lines of chemotherapy.
Back to search page